Tunisia

The primary regulatory authority responsible for health products in Tunisia is the Direction de la Pharmacie et du Médicament (DPM), operating under the Ministry of Health. The overarching legislative framework is established by Law No. 85-91 of 1985 on the organization of pharmaceutical activities, as amended, along with subsequent ministerial decrees governing the registration, importation, and distribution of pharmaceuticals, medical devices, and diagnostics. The general approval process requires submission of a registration dossier to the DPM, followed by technical review by expert committees, including the Commission Technique Consultative, which evaluates safety, efficacy, and quality data before a marketing authorization (visa d'exploitation) is granted. Digital health products are subject to evolving oversight, with some components falling under health technology assessment considerations and others governed by general ICT regulations.

Applicants seeking registration in Tunisia must appoint a locally established representative or licensed importer, as foreign manufacturers cannot directly submit applications without a nationally registered commercial entity acting on their behalf. Dossiers are generally required to follow the Common Technical Document (CTD) format, with supporting documentation in French or Arabic, and must include product quality data, clinical evidence, and country-of-origin regulatory approval where applicable. Tunisia increasingly references international standards such as those from the World Health Organization (WHO) prequalification program and the European Medicines Agency (EMA) as supporting benchmarks, particularly for pharmaceuticals and in vitro diagnostics. Recent reform efforts have focused on streamlining review timelines, digitalizing submission processes, and harmonizing standards with African Union and Arab League regulatory initiatives, including engagement with the African Medicines Regulatory Harmonization (AMRH) framework.

Public procurement of health products in Tunisia is centralized primarily through the Pharmacie Centrale de Tunisie (PCT), a state-owned entity responsible for purchasing, storing, and distributing pharmaceuticals, medical devices, vaccines, and diagnostics to public health facilities nationwide. The PCT conducts national tenders on behalf of the Ministry of Health, and participation requires prior registration of products with the DPM as well as compliance with PCT-specific supplier qualification criteria. Budget allocation and procurement planning are coordinated between the Ministry of Health and the Ministry of Finance, with the public sector accounting for a significant share of total health product consumption. Regional health directorates (Directions Regionales de la Sante) manage distribution at the governorate level, but procurement authority remains largely centralized at the national level.

The private sector constitutes a parallel and significant channel for health product distribution in Tunisia, with products flowing through licensed wholesalers and pharmacies operating under DPM oversight. Multinational companies and local distributors supply private hospitals, clinics, and community pharmacies independently of PCT mechanisms. Donor-funded procurement, while less prominent than in lower-income African markets, exists through cooperation with organizations such as UNICEF, the World Health Organization, and the Global Fund, particularly for communicable disease programs including tuberculosis and HIV. Tunisia has implemented policies encouraging local pharmaceutical manufacturing, reflected in preferential pricing and registration incentives for domestically produced generics, and the government has expressed strategic interest in expanding local production capacity through public-private partnerships as part of broader industrial health policy objectives.